Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent
The recent Tylenol scare felt like a slap in the face to the neurodivergent community in terms of needed research
doi: 10.3389/fphar.2026.1783888 Received 08 January 2026 Revised 23 February 2026 Accepted 23 March 2026 Published 15 April 2026 Volume 17 - 2026 Edited by Jos Roberto de Oliveira Ferreira, Universidade Estadual de Cincias da Sade de Alagoas, Brazil Reviewed by Ruolan Li, University of Electronic Science and Technology of China, China Ramoji Kosuru, Versiti Blood Research Institute, United States Updates Copyright 2026 Scenna, Bej, Cesare, Persichitti, Cimini, DAngelo and Castelli
Hammond, C
But it's, um, it's not about the stuff really for (00:15:00) patients
Cereb Cortex 15:448459 Dallas S, Miller DS, Bendayan R (2006) Multidrug resistance-associated proteins: expression and function in the central nervous system
